MedTrace Logo

A Study to Evaluate the Safety and Immunogeneicity of Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults

NCT03549208 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2018-06-13

No results posted yet for this study

Summary

phase-1 study pneumococcal conjugate vaccine study in healthy adults

Conditions

  • Pneumococcal Infection

Interventions

BIOLOGICAL

LBVE01

Multivalent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh

BIOLOGICAL

LBVE02

Multivalent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh

BIOLOGICAL

Prevnar13

13-valent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh

Sponsors & Collaborators

  • LG Chem

    lead INDUSTRY

Principal Investigators

  • Myoung-don Oh, M.D. · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-07-01
Primary Completion
2019-04-01
Completion
2019-07-25

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03549208 on ClinicalTrials.gov